Reveal LINQ vs LINQ II Insertable Cardiac Monitor

Direct competitors — feature-level head-to-head below. Comparability 95/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Medtronic
VS

AI Verdict

Reveal LINQ and LINQ II are both Medtronic insertable cardiac monitors that leverage AccuRhythm™ AI for continuous ECG monitoring and arrhythmia detection. While Reveal LINQ is noted for its exceptionally small size and up to three years of monitoring, LINQ II offers an extended monitoring period of up to 4.5 years, remote programming capabilities, and additional features like an innovative PVC detection algorithm and pediatric indication. These tools are direct competitors, with LINQ II appearing to be an advanced iteration of the Reveal LINQ platform.

Choose Reveal LINQ if…

Choose Reveal LINQ if a patient requires a highly discreet, minimally invasive cardiac monitoring solution with a simplified insertion procedure. This tool is particularly well-suited for diagnostic periods up to three years, leveraging AccuRhythm™ AI algorithms to accurately detect arrhythmias like atrial fibrillation and cryptogenic stroke while minimizing false alerts.

View Reveal LINQ →

Choose LINQ II Insertable Cardiac Monitor if…

Choose LINQ II if a patient needs extended cardiac monitoring for up to 4.5 years, or if remote programming capabilities are crucial for ongoing device management without frequent in-person visits. This device is also specifically indicated for pediatric patients aged 2 and older, and offers advanced algorithms for detailed PVC detection.

View LINQ II Insertable Cardiac Monitor →

For physicians evaluating Medtronic’s insertable cardiac monitors, both the Reveal LINQ and LINQ II leverage AccuRhythm™ AI algorithms for accurate arrhythmia detection, including atrial fibrillation and syncope. The Reveal LINQ is best suited for its compact size and established presence, offering up to three years of continuous ECG monitoring. It utilizes a bedside patient monitor for data transmission and a mobile app for clinicians, making it a reliable choice for long-term, discreet monitoring in a broad patient population.

The LINQ II, while also an insertable cardiac monitor, distinguishes itself with enhanced features like remote programming capability and an extended monitoring duration of up to 4.5 years. This makes the LINQ II particularly advantageous for patients requiring even longer-term surveillance or those who could benefit from remote device adjustments. The key practical difference lies in the LINQ II’s remote programming and longer battery life, offering greater flexibility and potentially reducing the need for in-person clinic visits for certain device adjustments. Physicians prioritizing the smallest possible device and a proven track record might lean towards the Reveal LINQ, while those seeking extended monitoring and the convenience of remote programming for managing patient care should consider the LINQ II.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Reveal LINQ LINQ II Insertable Cardiac Monitor
Pricing Contact vendor for pricing Enterprise
Deployment Implantable medical device with a bedside patient monitor (MyCareLink™) for data transmission and a mobile app (Reveal LINQ™ Mobile Manager) for clinicians. Hybrid
FDA Status Yes AI-estimated Cleared AI-estimated
HIPAA Unknown Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

LINQ II Insertable Cardiac Monitor

Tool B (LINQ II) offers remote programming capability and a longer battery life of up to 4.5 years, which directly reduces the need for in-person clinic visits for device adjustments and replacements, enhancing convenience for both patients and clinicians. The 'MyCareLink Relayu2122 home communicator option' also provides additional flexibility for data transmission compared to Tool A's MyCareLinku2122 Patient Monitor.

Clinical Value

LINQ II Insertable Cardiac Monitor

Tool B (LINQ II) provides a significantly longer continuous monitoring period of up to 4.5 years compared to Tool A's three years, increasing the likelihood of detecting infrequent arrhythmias. Furthermore, Tool B includes an 'Innovative PVC detection algorithm' and a 'Pediatric indication (ages 2+)', broadening its diagnostic capabilities and applicable patient population.

Pricing & Value

LINQ II Insertable Cardiac Monitor

While both tools have non-public, negotiated enterprise pricing, Tool B (LINQ II) offers superior features such as extended monitoring duration and remote programming. These advancements likely translate to a better long-term value proposition by potentially reducing follow-up costs and expanding the device's utility over its lifespan.

Enterprise Readiness

LINQ II Insertable Cardiac Monitor

Both tools are from Medtronic, are FDA cleared, and HIPAA compliant, indicating a strong foundation. However, Tool B (LINQ II) explicitly states its 'target_size' from solo to large health systems and highlights that 'More than 1 million patients have received a Medtronic ICM worldwide,' demonstrating a broader proven track record and scalability within enterprise environments.

Innovation

LINQ II Insertable Cardiac Monitor

While Tool A (Reveal LINQ) was innovative for being the 'world's smallest' ICM, Tool B (LINQ II) introduces significant functional innovations. These include remote programming capability, an extended monitoring duration of up to 4.5 years, and an 'Innovative PVC detection algorithm,' representing a clear advancement in patient management and diagnostic precision.

Support & Docs

Tie

Both products are manufactured by Medtronic, a well-established medical device company, implying a similar standard of corporate support and documentation. The provided information does not offer specific details on the quality, breadth, or accessibility of support and documentation that would allow for a clear distinction between the two tools.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Reveal LINQ LINQ II Insertable Cardiac Monitor
Name Reveal LINQ LINQ II Insertable Cardiac Monitor
Description Medtronic Reveal LINQ is a tiny, implantable cardiac monitor that continuously records ECG for up to three years, utilizing AccuRhythmu2122 AI algorithms to accurately detect and diagnose cardiac arrhythmias, including atrial fibrillation, cryptogenic stroke, and unexplained syncope. The Medtronic LINQ II is an advanced, AI-powered insertable cardiac monitor providing long-term, continuous heart rhythm monitoring with remote programming and enhanced accuracy for diagnosing arrhythmias.
Tagline The world's smallest insertable cardiac monitor with AI-powered accuracy. Advanced insertable cardiac monitoring with AI-powered accuracy and remote management.
Continuous Monitoring Duration up to three years Up to 4.5 years
AI Algorithms AccuRhythmu2122 AI algorithms for reduced false alerts (AF and pause) AccuRhythmu2122 AI algorithms for enhanced accuracy; Innovative PVC detection algorithm
MRI Compatibility MRI Conditional (1.5T and 3T) with no post-insertion waiting MRI compatibility (1.5 and 3.0T)
Remote Programming Capability Not specified Remote programming capability

Videos

Demos, reviews, and walkthroughs featuring Reveal LINQ and LINQ II Insertable Cardiac Monitor.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

The Medtronic Reveal LINQ provides continuous ECG monitoring for up to three years. In contrast, the Medtronic LINQ II Insertable Cardiac Monitor offers an extended monitoring period of up to 4.5 years.
Both devices utilize AccuRhythmu2122 AI algorithms for accurate arrhythmia detection. The Reveal LINQ specifically highlights reduced false alerts for AF and pause, while the LINQ II also features an innovative PVC detection algorithm.
The Medtronic LINQ II Insertable Cardiac Monitor explicitly offers remote programming capability. The Reveal LINQ's features do not explicitly mention remote programming, focusing on wireless data transmission and clinician app management.
The Reveal LINQ is marketed as the world's smallest insertable cardiac monitor at 1.2 mL, suggesting a focus on minimal invasiveness and simplified insertion. The LINQ II does not specify its size, but both are designed for minimally invasive implantation.
The Medtronic LINQ II Insertable Cardiac Monitor has a pediatric indication for ages 2 and up. The Reveal LINQ's description does not specify a pediatric indication.
The Reveal LINQ uses the MyCareLinku2122 Patient Monitor for data transmission to the CareLinku2122 network and the Reveal LINQu2122 Mobile Manager app for clinicians. The LINQ II utilizes the MyCareLink Heartu2122 mobile app for data transmission and offers the MyCareLink Relayu2122 home communicator option.
AI Tool Finder
AI-powered search. Results may not be comprehensive.